Thiotepa, Cyclophosphamide, Clarithromycin and Cytarabine

Laborértékek

• 1. Have a history of cancer and have received any treatment for this tumor in the past 3 years, except for superficial bladder cancer, basal cell or squamous cell carcinoma of the skin, cervical intraepithelial carcinoma (CIN), or prostate epithelium Internal carcinogenesis (PIN); 2. Known to be serologically positive for HIV, active hepatitis B, active hepatitis C virus or syphilis; 3. Suffering from mental illness or other conditions and unable to cooperate with the requirements of research treatment and monitoring; 4. Pregnant patients or patients who cannot take appropriate contraceptive measures during treatment; 5. Received hematopoietic stem cell transplantation within the past 1 year; 6. Active heart disease, defined as one or more of the following:
  • Have a history of uncontrolled or symptomatic angina;
  • Myocardial infarction less than 6 months from study enrollment;
  • Have a history of arrhythmia that requires drug treatment or has severe clinical symptoms;
  • Uncontrolled or symptomatic congestive heart failure (>NYHA class 2);
  • The ejection fraction is lower than the lower limit of the normal range. 7. Patients who meet the following criteria:
  • <!-- -->
  • Major surgery (except diagnostic surgery) is planned within 4 weeks before enrollment or during the study period, or the surgical wound has not fully healed before enrollment;
  • Those who have received (attenuated) live vaccines within 4 weeks before enrollment;
  • Patients with suspected active or latent tuberculosis;
  • Participate in other clinical trials one month before enrollment 8. Those who the researcher believes are not suitable for enrollment

• 1. Voluntarily sign the informed consent form, which must be signed by the patient himself.
  • ALL patients confirmed by bone marrow cell morphology, immunology, and genetics; 3. PH+ALL patients who achieve s3CMR (definition: achieve molecular biological remission in the early stage of initial treatment (within 3 months) and maintain remission); 4. Ph-B-ALL patients who have reached MRD- after 3 courses of chemotherapy and continue to be MRD-; adult patients with Burkitt lymphoma and lymphoblastic lymphoma confirmed by histopathology and molecular genetics; 5. Adult patients with Burkitt lymphoma and lymphoblastoma, if the bone marrow is not involved, can achieve PR or above after induction; if the bone marrow is involved at the time of initial diagnosis, 3 courses of chemotherapy are required to reach MRD- and continue to be MRD-.
  • Patients receiving autologous hematopoietic stem cell transplantation (auto-HSCT); 7. Age ≥18 years and ≤65 years old, male or female; 8. Eastern Cooperative Oncology Group Performance Status (ECOG-PS) score of 0-2;